News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alexion (ALXN)'s Bloated Blockbuster Deal Still Haunts



2/17/2017 6:51:24 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
When Alexion Pharmaceuticals (ALXN) paid $8.4 billion to acquire Synageva Biopharma in May 2015, then CEO Lenny Bell told investors the high price tag was justified because Kanuma, Synageva's lead rare disease drug, would become a billion-dollar product.

Behind Kanuma in the Synageva deal, Alexion was also getting SBC-103, a second rare disease drug that would bolster the company's pipeline, Bell said.


Read at The Street.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES